US Pharma MarketingTyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data
Tyra Biosciences released Phase 2 data for dabogratinib, targeting bladder cancer, aiming to rival J&J Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and…
Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step toward that goal — although you just might have to squint ...
Source: Endpoints News